Taxane-Containing Chemo Associated With Persistent Alopecia
However, many patients experience improvements in hair density with standard alopecia treatments
Alopecia
Second Alopecia Areata Trial Demonstrates Hair Regrowth With Baricitinib
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.
Baricitinib Improves Hair Regrowth in Alopecia Areata Trial
Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.
Disproportionality Signal Found for Suicidality in Finasteride Users
Younger patients and those with alopecia have significant disproportionality signals for increased suicidality
Investigational Oral JAK Inhibitor Gets Breakthrough Tx Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to CTP-543 (Concert Pharmaceuticals), an oral Janus kinase (JAK) inhibitor for alopecia areata.
Baricitinib Receives Breakthrough Therapy Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
Finasteride Uses, Efficacy Examined in Female Patients
Off-label use has become more common in women for treatment of alopecia and hirsutism.
Oral JAK3 Inhibitor Granted Breakthrough Tx Designation for Alopecia Areata
PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.
Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss
Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.
Endocrine Therapy-Induced Alopecia Seen in Breast Cancer
“Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents,” the authors write.
